Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival.

[1]  D. Murphy,et al.  Knowing what’s growing: Why ductal and intraductal prostate cancer matter , 2020, Science Translational Medicine.

[2]  Jiefeng He,et al.  Screening of significant biomarkers related with prognosis of liver cancer by lncRNA‐associated ceRNAs analysis , 2020, Journal of cellular physiology.

[3]  Justin Bedő,et al.  BioShake: a Haskell EDSL for bioinformatics workflows , 2019, PeerJ.

[4]  M. Loda,et al.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. , 2019, European urology.

[5]  P. Nelson,et al.  Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. , 2019, JCO precision oncology.

[6]  A. Costello,et al.  Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression , 2018, BJU international.

[7]  F. Demichelis,et al.  RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer , 2018, Clinical Cancer Research.

[8]  A. Costello,et al.  Obesity suppresses tumor attributable PSA, affecting risk categorization. , 2018, Endocrine-related cancer.

[9]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[10]  W. Isaacs,et al.  Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer , 2018, The Prostate.

[11]  J. Lack,et al.  Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. , 2017, European urology focus.

[12]  D. Murphy,et al.  Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. , 2017, European urology.

[13]  P. Kantoff,et al.  Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Xia,et al.  Knockdown of anion exchanger 2 suppressed the growth of ovarian cancer cells via mTOR/p70S6K1 signaling , 2017, Scientific Reports.

[15]  Myung Soo Kim,et al.  Prognostic Significance of the Proportion of Ductal Component in Ductal Adenocarcinoma of the Prostate , 2017, The Journal of urology.

[16]  N. Xu,et al.  Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study , 2017, Oncotarget.

[17]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[18]  N. Dyson.  RB1: a prototype tumor suppressor and an enigma , 2016, Genes & development.

[19]  N. Corcoran,et al.  Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis , 2016, Clinical Cancer Research.

[20]  B. Delahunt,et al.  Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non‐prostatic origin: a comparative study , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[22]  J. Hicks,et al.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas , 2015, The Prostate.

[23]  Sanjay G. Patel,et al.  Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. , 2015, Urology.

[24]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[25]  B. Delahunt,et al.  Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists , 2014, Histopathology.

[26]  J. Godet,et al.  Ductal carcinoma of the prostate shows a different immunophenotype from high grade acinar cancer , 2013, Histopathology.

[27]  Haojie Huang,et al.  ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance. , 2013, Cancer letters.

[28]  L. Egevad,et al.  Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens , 2013, Virchows Archiv.

[29]  T. Tot,et al.  Immunohistochemical verification of ductal differentiation in prostate cancer , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[30]  J. Cashy,et al.  Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program , 2012, BJU international.

[31]  P. Humphrey.  Histological variants of prostatic carcinoma and their significance , 2012, Histopathology.

[32]  J. Epstein,et al.  Pathologic Stage of Prostatic Ductal Adenocarcinoma at Radical Prostatectomy: Effect of Percentage of the Ductal Component and Associated Grade of Acinar Adenocarcinoma , 2011, The American journal of surgical pathology.

[33]  T. Morgan,et al.  Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. , 2010, The Journal of urology.

[34]  E. Orihuela,et al.  Ductal prostate cancer: contemporary management and outcomes. , 2008, Urologic oncology.

[35]  P. Walsh,et al.  Prostatic duct adenocarcinoma. Findings at radical prostatectomy , 1991, Cancer.

[36]  M. Lagios,et al.  Endometrial (papillary) carcinoma of the prostatic utricle—response to orchiectomy. A case report , 1973, Cancer.

[37]  M. Spahn.  Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. , 2018, European urology.

[38]  Jonathan I. Epstein,et al.  WHO Classification of of Tumours of the Urinary System and Male Genital Organs , 2016 .

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.